What is Jude Bio?
Jude Bio is at the forefront of pioneering oligonucleotide medicines specifically designed for delivery to the kidney. This innovative approach opens new avenues for RNA-based therapies targeting both systemic and renal diseases. The company leverages its proprietary STRIKE (Selectively Targeting RNA Into KidnEy) platform, which utilizes a natural, endogenous mechanism to direct oligonucleotide medicines to the kidney. Jude Bio's initial drug programs focus on ligand-siRNA conjugate drugs engineered for receptor-mediated uptake by specific kidney cell types, aiming to achieve gene silencing of disease-modifying target genes.
How much funding has Jude Bio raised?
Jude Bio has raised a total of $100M across 1 funding round:
Angel/Seed
$100M
Angel/Seed (2024): $100M with participation from TCG, Atlas Venture, and The Column Group
Key Investors in Jude Bio
TCG
TCG Inc delivers specialized information technology and management advisory services to federal government agencies, combining technical expertise with deep understanding of public sector operations. The company focuses on four core competencies: Agile development methodologies, federal shared services optimization, budget formulation and execution support, and health science analytics.
Atlas Venture
Atlas Venture is a pioneering early-stage venture capital firm focused on creating and building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines. The firm partners with exceptional life science entrepreneurs to support the launch and growth of innovative biotech startups.
The Column Group
The Column Group (TCG) is a venture ecosystem focused on advancing scientific innovation in the life sciences sector. With a history of funding key advancements in biotechnology, TCG has supported the formation and growth of 55 companies, generating $4.0 billion in returns for its partners.
What's next for Jude Bio?
With this major enterprise-level funding, Jude Bio is poised to accelerate its research and development initiatives, particularly in advancing its pipeline of oligonucleotide therapies for kidney-related diseases. The strategic investment signals strong confidence from backers in the company's unique STRIKE platform and its potential to revolutionize treatment paradigms. Future endeavors will likely involve further clinical validation, expansion of drug programs, and strategic partnerships to broaden market reach and therapeutic impact.
See full Jude Bio company page
